A Controlled Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness

This study is currently recruiting participants.

Verified by Bronx Veterans Medical Research Foundation, Inc, June 2008

First Received: June 3, 2008 Last Updated: June 4, 2008 History of Changes

Sponsors and Collaborators:	Bronx Veterans Medical Research Foundation, Inc U.S. Army Medical Research and Materiel Command
Information provided by:	Bronx Veterans Medical Research Foundation, Inc
ClinicalTrials.gov Identifier:	NCT00691067

Purpose

We propose to conduct placebo-controlled trial of the glucocorticoid receptor antagonist mifepristone in Gulf War veterans (GWV) with chronic multisymptom illness (CMI) to examine its effects on physical and mental health and cognitive functioning. In addition, we propose to examine whether HPA axis biomarkers or their response to mifepristone are useful predictors of clinical response.

Condition	Intervention	Phase
Chronic Multisymptom Illness in Gulf War Veterans	Drug: mifepristone Drug: placebo	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Crossover Assignment, Efficacy Study
Official Title:	A Randomized, Double-Blind Placebo-Controlled Crossover Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness

Resource links provided by NLM:

Drug Information available for: Mifepristone

U.S. FDA Resources

Further study details as provided by Bronx Veterans Medical Research Foundation, Inc:

Primary Outcome Measures:

change in the health components score of the veterans RAND 36-item health survey (VR-36) [ Time Frame: baseline, every two weeks, endpoint ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

cognitive functioning and measures of depression, fatigue and PTSD [ Time Frame: baseline and endpoint ] [ Designated as safety issue: No ]

Estimated Enrollment:	40
Study Start Date:	May 2008
Estimated Study Completion Date:	May 2011
Estimated Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)

Intervention Details:

200 mg po per day x 6 weeks

placebo

Eligibility

Ages Eligible for Study:	35 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Veteran of the 1991 Gulf War
Veteran meets criteria for multisymptom illness

Exclusion Criteria:

Veteran lacks the capacity to provide consent.
Veteran has a major medical or neurological disorder or traumatic brain injury
Veteran has morning plasma cortisol level less than 5 mcg/dl or a history of adrenal insufficiency
Veteran has a fasting blood glucose ≥ 110 mcg/dl
Veteran is taking oral corticosteroids
Veteran has a lifetime diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder
Veteran has been psychiatrically hospitalized or attempted suicide within the previous 2 years
Veteran has current suicidal ideation
Veteran is pregnant or breastfeeding or plans to become pregnant within the year (male or female) not willing to use appropriate forms of contraception during the study and for at least 90 days post treatment.
Women veterans with diseases of the uterus by history or a family history of uterine cancer
Known allergy to mifepristone

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00691067

Contacts

Contact: Julia A Golier, M.D.

718-584-9000 ext 5196

julia.golier@va.gov

Locations

United States, New York
James J Peters VA Medical Center	Recruiting
Bronx, New York, United States, 10468
Contact: Julia A Golier, M.D. 718-584-9000 ext 5196 julia.golier@va.gov
Principal Investigator: Julia A Golier, M.D.

Sponsors and Collaborators

Bronx Veterans Medical Research Foundation, Inc

U.S. Army Medical Research and Materiel Command

Investigators

Principal Investigator:

Julia A Golier, M.D.

James J Peters VA Medical Center

More Information

No publications provided

Responsible Party:	James J Peters VA Medical Center ( Julia Golier, M.D. )
Study ID Numbers:	GW060048
Study First Received:	June 3, 2008
Last Updated:	June 4, 2008
ClinicalTrials.gov Identifier:	NCT00691067 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Contraceptive Agents
Hormone Antagonists
Contraceptives, Oral
Hormones, Hormone Substitutes, and Hormone Antagonists

Contraceptive Agents, Female
Mifepristone
Contraceptives, Postcoital
Hormones

Additional relevant MeSH terms:

Abortifacient Agents, Steroidal
Contraceptives, Postcoital, Synthetic
Contraceptive Agents
Hormone Antagonists
Contraceptives, Oral
Physiological Effects of Drugs
Contraceptive Agents, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Mifepristone

Reproductive Control Agents
Luteolytic Agents
Contraceptives, Postcoital
Pharmacologic Actions
Therapeutic Uses
Abortifacient Agents
Menstruation-Inducing Agents
Contraceptives, Oral, Synthetic

ClinicalTrials.gov processed this record on July 06, 2009